Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Axsome Therapeutics
(NASDAQ:AXSM)
Intraday
$72.50
-1.18
[-1.60%]
After-Hours
$72.50
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$72.50
-1.18
[-1.60%]
At close: May 10
$72.50
0
[0.00%]
After Hours: 4:00PM EDT
Get Report
Watch
Q1 2024 Earnings were released on Mon May 6th, before the market open
The most recent conference call was at 8:00 AM, 7 days ago
Click to view past webcast
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Axsome Therapeutics Stock (NASDAQ:AXSM)
Axsome Therapeutics Stock (NASDAQ: AXSM)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, May 08, 2024
Mizuho Maintains Buy on Axsome Therapeutics, Lowers Price Target to $106
Benzinga Newsdesk
-
4 days ago
Tuesday, May 07, 2024
Citigroup Maintains Buy on Axsome Therapeutics, Lowers Price Target to $125
Benzinga Newsdesk
-
5 days ago
Baird Maintains Outperform on Axsome Therapeutics, Raises Price Target to $112
Benzinga Newsdesk
-
5 days ago
HC Wainwright & Co. Reiterates Buy on Axsome Therapeutics, Maintains $190 Price Target
Benzinga Newsdesk
-
5 days ago
Monday, May 06, 2024
Axsome Therapeutics Q1 2024 GAAP EPS $(1.44) Misses $(1.21) Estimate, Sales $74.999M Beat $73.295M Estimate
Benzinga Newsdesk
-
6 days ago
Monday, April 29, 2024
Peeling Back The Layers: Exploring Axsome Therapeutics Through Analyst Insights
Benzinga Insights
-
Apr 29, 2024, 10:01AM
Morgan Stanley Upgrades Axsome Therapeutics to Overweight, Raises Price Target to $115
Benzinga Newsdesk
-
Apr 29, 2024, 5:27AM
Wednesday, April 10, 2024
Analyst Ratings For Axsome Therapeutics
Benzinga Insights
-
Apr 10, 2024, 12:00PM
Cantor Fitzgerald Reiterates Overweight on Axsome Therapeutics, Maintains $107 Price Target
Benzinga Newsdesk
-
Apr 10, 2024, 9:35AM
Tuesday, April 02, 2024
HC Wainwright & Co. Maintains Buy on Axsome Therapeutics, Maintains $190 Price Target
Benzinga Newsdesk
-
Apr 2, 2024, 8:53AM
Monday, April 01, 2024
Axsome Therapeutics Has Initiated ENGAGE Phase 3 Trial Of Solriamfetol, An Investigational Treatment For Binge Eating Disorder In Adults
Benzinga Newsdesk
-
Apr 1, 2024, 7:28AM
Thursday, March 28, 2024
Mizuho Maintains Buy on Axsome Therapeutics, Raises Price Target to $109
Benzinga Newsdesk
-
Mar 28, 2024, 10:06AM
Tuesday, March 26, 2024
Truist Securities Maintains Buy on Axsome Therapeutics, Maintains $150 Price Target
Benzinga Newsdesk
-
Mar 26, 2024, 9:23AM
Tesla To $120? Here Are 10 Top Analyst Forecasts For Tuesday
Avi Kapoor
-
Mar 26, 2024, 8:30AM
RBC Capital Maintains Outperform on Axsome Therapeutics, Raises Price Target to $128
Benzinga Newsdesk
-
Mar 26, 2024, 8:09AM
Citigroup Maintains Buy on Axsome Therapeutics, Raises Price Target to $127
Benzinga Newsdesk
-
Mar 26, 2024, 7:34AM
HC Wainwright & Co. Maintains Buy on Axsome Therapeutics, Raises Price Target to $190
Benzinga Newsdesk
-
Mar 26, 2024, 6:15AM
Monday, March 25, 2024
What's Going On Neurology-Focused Axsome Therapeutics' Stock On Monday?
Vandana Singh
-
Mar 25, 2024, 12:03PM
Axsome Therapeutics shares are trading higher the company's AXS-12 achieved primary endpoint in the SYMPHONY phase 3 trial in narcolepsy.
Benzinga Newsdesk
-
Mar 25, 2024, 6:41AM
Axsome Therapeutics' AXS-12 (Reboxetine) Achieved The Primary Endpoint And Significantly Reduced The Frequency Of Cataplexy Attacks As Compared To Placebo In Narcolepsy Patients In SYMPHONY Phase 3 Trial
Benzinga Newsdesk
-
Mar 25, 2024, 6:32AM
Wednesday, March 20, 2024
HC Wainwright & Co. Reiterates Buy on Axsome Therapeutics, Maintains $180 Price Target
Benzinga Newsdesk
-
Mar 20, 2024, 6:46AM
Tuesday, March 19, 2024
What Analysts Are Saying About Axsome Therapeutics Stock
Benzinga Insights
-
Mar 19, 2024, 9:01AM
Axsome Therapeutics Announced The First Patient Has Been Dosed In PARADIGM Phase 3 Trial Of Solriamfetol, An Investigational Treatment For Major Depressive Disorder
Benzinga Newsdesk
-
Mar 19, 2024, 7:01AM
Baird Initiates Coverage On Axsome Therapeutics with Outperform Rating, Announces Price Target of $108
Benzinga Newsdesk
-
Mar 19, 2024, 4:48AM
Monday, March 04, 2024
HC Wainwright & Co. Reiterates Buy on Axsome Therapeutics, Maintains $180 Price Target
Benzinga Newsdesk
-
Mar 4, 2024, 7:49AM
Tuesday, February 27, 2024
What Analysts Are Saying About Axsome Therapeutics Stock
Benzinga Insights
-
Feb 27, 2024, 11:00AM
Mizuho Maintains Buy on Axsome Therapeutics, Lowers Price Target to $108
Benzinga Newsdesk
-
Feb 27, 2024, 10:41AM
Wednesday, February 21, 2024
Guggenheim Maintains Buy on Axsome Therapeutics, Raises Price Target to $125
Benzinga Newsdesk
-
Feb 21, 2024, 12:57PM
RBC Capital Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $123
Benzinga Newsdesk
-
Feb 21, 2024, 10:09AM
Cantor Fitzgerald Maintains Overweight on Axsome Therapeutics, Lowers Price Target to $103
Benzinga Newsdesk
-
Feb 21, 2024, 9:38AM
Tuesday, February 20, 2024
CORRECTION: Axsome Therapeutics Q4 Adjusted EPS $(0.73) Beats $(1.15) Estimate, Sales $71.53M Beat $67.69M Estimate
Benzinga Newsdesk
-
Feb 20, 2024, 7:03PM
Neurology-Focused Axsome Therapeutics Reports Deeper Than Expected Q4 Loss, Updates Upcoming Pipeline Milestones
Vandana Singh
-
Feb 20, 2024, 1:05PM
Cantor Fitzgerald Reiterates Overweight on Axsome Therapeutics, Maintains $108 Price Target
Benzinga Newsdesk
-
Feb 20, 2024, 12:32PM
Axsome Therapeutics shares are trading lower after the company reported worse-than-expected Q4 EPS results.
Benzinga Newsdesk
-
Feb 20, 2024, 11:55AM
Earnings Scheduled For February 20, 2024
Benzinga Insights
-
Feb 20, 2024, 6:52AM
Monday, February 19, 2024
Earnings Outlook For Axsome Therapeutics
Benzinga Insights
-
Feb 19, 2024, 12:01PM
Friday, February 16, 2024
Mizuho Maintains Buy on Axsome Therapeutics, Raises Price Target to $112
Benzinga Newsdesk
-
Feb 16, 2024, 6:45PM
Tuesday, February 06, 2024
UBS Bullish On This Depression Drug Maker, Says Alzheimer's Agitation Data Is Attractive Catalyst
Vandana Singh
-
Feb 6, 2024, 2:19PM
The Latest Analyst Ratings For Axsome Therapeutics
Benzinga Insights
-
Feb 6, 2024, 8:00AM
UBS Initiates Coverage On Axsome Therapeutics with Buy Rating, Announces Price Target of $111
Benzinga Newsdesk
-
Feb 6, 2024, 7:49AM
Friday, January 26, 2024
Cramer Praises Asset Manager's 'Amazing Quarter,' But As For SolarEdge? 'Too Hard To Own'
Avi Kapoor
-
Jan 26, 2024, 9:06AM
Thursday, January 25, 2024
Axsome Depression Drug's Commercial Success, Pipeline Potential Undervalued, Analyst Says
Vandana Singh
-
Jan 25, 2024, 3:08PM
RBC Capital Initiates Coverage On Axsome Therapeutics with Outperform Rating, Announces Price Target of $126
Benzinga Newsdesk
-
Jan 25, 2024, 6:05AM
Monday, January 22, 2024
Axsome Therapeutics shares are trading higher after Cantor Fitzgerald reiterated its Overweight rating on the stock.
Benzinga Newsdesk
-
Jan 22, 2024, 3:40PM
Cantor Fitzgerald Reiterates Overweight on Axsome Therapeutics, Maintains $108 Price Target
Benzinga Newsdesk
-
Jan 22, 2024, 8:52AM
Tuesday, January 16, 2024
The Analyst Landscape: 6 Takes On Axsome Therapeutics
Benzinga Insights
-
Jan 16, 2024, 10:00AM
Piper Sandler Maintains Overweight on Axsome Therapeutics, Raises Price Target to $113
Benzinga Newsdesk
-
Jan 16, 2024, 9:42AM
Thursday, January 04, 2024
Axsome Therapeutics shares are trading higher after the company reported preliminary Q4 net product revenue above estimates.
Benzinga Newsdesk
-
Jan 4, 2024, 10:53AM
Axsome Therapeutics Expects Preliminary 4Q Net Product Revenue Of $71M Vs. $66.44M Estimate; Expects FY23 Net Product Revenue Of $204M Vs. $265.95M Estimate
Benzinga Newsdesk
-
Jan 4, 2024, 7:16AM
Tuesday, December 26, 2023
HC Wainwright & Co. Reiterates Buy on Axsome Therapeutics, Maintains $180 Price Target
Benzinga Newsdesk
-
Dec 26, 2023, 6:22AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch